Paper17868596
First tuberculosis cases in Italy resistant to all tested drugs.
Migliori GB and 4 others. Euro Surveill, 2007. Cited by 126 papers, by iCite.
Cite this record
ConductScience Library. First tuberculosis cases in Italy resistant to all tested drugs. Papers, record 17868596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17868596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Drug Resistance, Microbial | Major topic |
| Treatment Failure | Major topic |
| Tuberculosis | Major topic |
| Adolescent | |
| Female | |
| Humans | |
| Italy |
Source PubMed
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42436825 | Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy. | J R Soc N Z | 2026 | https://conductscience.org/library/papers/42436825 | PubMed |
| 36964456 | Anti-tubercular activity evaluation of natural compounds by targeting Mycobacterium tuberculosis resuscitation promoting factor B inhibition: An in silico study. | Mol Divers | 2024 | https://conductscience.org/library/papers/36964456 | PubMed |
| 35479020 | Discovery of quinolone derivatives as antimycobacterial agents. | RSC Adv | 2021 | https://conductscience.org/library/papers/35479020 | PubMed |
| 34938089 | Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review. | Infect Drug Resist | 2021 | https://conductscience.org/library/papers/34938089 | PubMed |
| 33762833 | Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study. | Infect Drug Resist | 2021 | https://conductscience.org/library/papers/33762833 | PubMed |
| 33330374 | Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. | Front Chem | 2020 | https://conductscience.org/library/papers/33330374 | PubMed |
| 32676151 | 2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. | ACS Med Chem Lett | 2020 | https://conductscience.org/library/papers/32676151 | PubMed |
| 32014024 | A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic. | BMC Med | 2020 | https://conductscience.org/library/papers/32014024 | PubMed |
| 31985348 | ATP-binding cassette (ABC) import systems of Mycobacterium tuberculosis: target for drug and vaccine development. | Emerg Microbes Infect | 2020 | https://conductscience.org/library/papers/31985348 | PubMed |
| 31782209 | Synthesis, evaluation, molecular docking, and molecular dynamics studies of novel N-(4-[pyridin-2-yloxy]benzyl)arylamine derivatives as potential antitubercular agents. | Drug Dev Res | 2020 | https://conductscience.org/library/papers/31782209 | PubMed |
| 30839915 | Dynamic model of tuberculosis considering multi-drug resistance and their applications. | Infect Dis Model | 2018 | https://conductscience.org/library/papers/30839915 | PubMed |
| 30618776 | Genome Sequences and Comparative Analysis of Two Extended-Spectrum Extensively-Drug Resistant Mycobacterium tuberculosis Strains. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30618776 | PubMed |
| 30617959 | The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. | Drugs | 2019 | https://conductscience.org/library/papers/30617959 | PubMed |
| 30459198 | Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment. | mBio | 2018 | https://conductscience.org/library/papers/30459198 | PubMed |
| 30081525 | Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold. | Molecules | 2018 | https://conductscience.org/library/papers/30081525 | PubMed |
| 29033842 | Addressing the Challenges of Tuberculosis: A Brief Historical Account. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/29033842 | PubMed |
| 28840010 | Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. | J Thorac Dis | 2017 | https://conductscience.org/library/papers/28840010 | PubMed |
| 28178199 | Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28178199 | PubMed |
| 28096979 | Bibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015). | Multidiscip Respir Med | 2016 | https://conductscience.org/library/papers/28096979 | PubMed |
| 28066398 | Insect Vectors of Disease: Untapped Reservoirs for New Antimicrobials? | Front Microbiol | 2016 | https://conductscience.org/library/papers/28066398 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17868596
GET https://conductscience.org/api/papers/v1/17868596/cited_by?page=2